UK clinical-stage neurokinin receptor specialist company NeRRe Therapeutics has appointed Mary Kerr as chief executive.
Prior to joining NeRRe, Dr Kerr held a range of senior leadership roles and joins from GlaxoSmithKline (LSE: GSK), where she was senior vice president and global franchise leader for its immuno-inflammation and infectious diseases portfolio.
Martin Edwards, chairman of NeRRe, said: “At this critical stage of the company development, Mary is a great addition to the NeRRe Therapeutics team and I am delighted to welcome her. Her broad range of business skills and experience will provide invaluable direction to the company and the future development of its rich portfolio.”
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze